Disclosed is the use of a coagulation inhibiting amount of a N-(S-chloro-pyridin-2-yl)-2-(4-imido-benzoyl-amino)-S-methoxybenzamide of Formula II or pharmaceutically acceptable salt thereof, in the manufacture of a medicament form inhibiting coagulation in a human patient in need thereof, wherein the coagulation inhibiting amount of the compound is an aggregate daily dose of between about 0.1 and about 2.0 mg/kg.